Archives: 2019-10-01

Potential Solutions To Current Pricing Models For Cell And Gene Therapies

Source: Life Science Leader Headlines about high-priced cell and gene therapies specifically can cause sticker shock for the patient. Exhibit A: Novartis’ Zolgensma, the spinal muscular atrophy (SMA) gene therapy treatment, priced at $2.125 million, is the world’s most expensive drug to date. But cell and gene therapies are their own animals; the differences between

Read More